Open Access

Oncocytic-type intraductal papillary mucinous neoplasm (IPMN)-derived invasive oncocytic pancreatic carcinoma with brain metastasis - a case report

  • Kun-Chun Chiang1, 2,
  • Chi-Chang Yu3,
  • Jim-Ray Chen4,
  • Yu-Ting Huang5,
  • Cheng-Cheng Huang4,
  • Chun-Nan Yeh3,
  • Chien-Sheng Tsai6,
  • Li-Wei Chen7,
  • Hsien-Cin Chen8,
  • Jun-Te Hsu3,
  • Cheng-Hsu Wang9, 10Email author and
  • Huang-Yang Chen1, 10Email author
Contributed equally
World Journal of Surgical Oncology201210:138

https://doi.org/10.1186/1477-7819-10-138

Received: 21 February 2012

Accepted: 9 July 2012

Published: 9 July 2012

Abstract

Pancreatic cancer is a lethal disease without effective treatments at present. It ranks as s as 4th and 5th in cancer-related mortality in the western countries and worldwide. Locally advanced pancreatic duct carcinoma (PDAC) and metastatic PDAC, usually found the metastases over liver, peritoneum, or lung, have been shown to be with dismal prognosis. Brain metastasis is a rare entity and most cases reported before were found post-mortem. Intraductal papillary mucinous neoplasms of the pancreas (IPMN) has been deemed as a precursor of PDAC with very slow progression rate. Here we reported a case diagnosed with IPMN-derived PDAC with brain metastasis. After surgeries for PDAC and brain metastasis, subsequent chemotherapy and radiotherapy were also given. One and half year after surgery, this patient is still living with good performance status, which may warrant individualization of therapeutic strategy for PDAC with only brain metastasis.

Keywords

Brain metastasis IPMN Pancreatic cancer Oncocytic IPMN

Background

Pancreatic duct adenocarcinoma (PDAC) is a lethal human malignancies with a very poor prognosis. PDAC ranks as the eighth and ninth most common cause of cancer-related mortality worldwide for men and women, respectively [1]. The overall 5-year survival rate of patients with PDAC is only 1–4% approximately, which is possibly contributable to the aggressive characteristics of PCA [1]. PCA usually presents with early local spread and metastasis and resistance to traditional radiotherapy and systemic chemotherapies. At present, radical surgical resection remains the cornerstone of treatment. For advanced PDAC, the treatment strategy tends to be palliative.

Intraductal papillary mucinous neoplasms of the pancreas (IPMN) has been deemed as a precursor of PDAC with very slow progression rate. Here we reported a case diagnosed with IPMN-derived PDAC with brain metastasis. After aggressive surgeries for PDAC and brain metastasis and subsequent chemotherapy and radiotherapy, this patient is still l living well at the time of writing, which may encourages an aggressive treatment strategy against patients with PDAC with brain metastasis.

Case presentation

A 54-year-old male patient with an unexceptional medical history complained of several episodes of right-sided weakness and tripping in November, 2009. After one episode of tumbling on January 2, 2010, he was brought to our emergency department by his family. Data from blood biochemistry and other blood tests were all within normal ranges. Due to the presence of neurologic symptoms and signs, a computed tomography (CT) scan of the patient’s brain was performed. The scan revealed a 2.9-cm low-density mass over the left frontal lobe, with peripheral rim enhancement and extensive perifocal edema reaching the corpus callosum, and crossing the midline (Figure 1A).
Figure 1

Computed tomography (CT) and magnetic resonance (MR) imaging. (a) Axial contrast-enhanced computed tomography of the brain shows a ring-enhancing lesion (arrow) in the left frontal lobe with perifocal edema. (b) Axial contrast-enhanced CT of abdomen shows a hypodense lesion (arrow) in the uncinate process of the pancreas with minimal encasement of the superior mesenteric vein. (c) 1 C T2-weighted image shows a mildly hyperintense mass (arrow) in the uncinate process of the pancreas with minimal encasement of the superior mesenteric vein (arrow head). (d) 1D MR cholangiopancreatography image shows dilatation of the pancreatic duct with abrupt termination (arrow). No dilatation of the biliary tree is noted.

A craniotomy was conducted on January 15, in the expectation of finding a brain abscess or tumor. During the operation, the cystic lesion was shown to contain no bacteria; the tumor was then resected subtotally due to its proximity to the motor area. The final pathology report indicated that the tumor was composed of branching complex papillae and occasional tubules (Figure 2A), with abundant oncocytic cytoplasm, large round nuclei with prominent nucleoli, and frequent mitoses (Figure 2B). Immunohistochemically, the tumor cells stained positively for cytokeratin 7, but were negative for cytokeratin 20, thyroid transcription factor 1 (TTF1), caudal-related homeobox transcription factor 2 (CDX2), and prostate-specific antigen, which indicated a metastatic rather than a primary brain tumor, which was unlikely to be derived from lung, gastrointestinal tract, or lung.
Figure 2

Histological examination of the resected brain tumor. (a) The brain tumor shows complex branching papillary structures with occasional tubular formation. (b) The tumor cells present large round nuclei with prominent nucleoli and abundant oncocytic cytoplasm. Mitoses are frequently seen.

A subsequent CT scan of chest and abdomen showed a 2.7-cm hypodense lesion in the uncinate process of the pancreas with pancreatic duct dilatation, suggesting pancreatic cancer (Figure 1B). Magnetic resonance cholangiopancreaticography (MRCP) (Figure 1C, D) was performed, revealing a 3.2-cm mass in the uncinate process of the pancreas with encasement of the superior mesenteric vein and pancreatic duct dilatation; the mass was radiologically staged as T4N0M0, according to the American Joint Committee on Cancer’s Cancer Staging Manual, 7th editionA laparotomy was performed on the patient on February 26, 2010. The cancer was adhesive to the portal vein and superior mesentery artery, but was separable from them. The regional lymph nodes were grossly normal. A pylorus-preserving Whipple operation was then conducted, after which the patient recovered well and was discharged 2 weeks later. The resected pancreas showed a 4.5 × 4 × 2-cm infiltrative gray-white tu>mor, with some dilated ducts containing polypoid tumors. Histologically, the solid tumor showed diffusely infiltrating tubules and branching complex papillae composed of oncocytic cells having mildly pleomorphic nuclei (Figures 3A and 3B). In contrast, the dilated ducts contained polypoid tumors composed of oncocytic cells forming complex arborizing papillae and tubules (Figures 3C and 3D). Obvious mucin production was noted throughout the tumors. These tumors were immunoreactive with the mucin proteins MUC1 (Figure 3E) and MUC5AC (Figure 3F), but negative for MUC2, MUC6, and CDX2.
Figure 3

Histological examination of the resected pancreatic tumor. (a) The pancreatic head tumor shows complex branching papillary structures and infiltrating tubules. (b) The tumor cells contain mildly pleomorphic nuclei and oncocytic cytoplasm. (c) The dilated duct displays a polypoid tumor with complex arborizing papillary and tubular structures. (d) The tumor cells exhibit mildly pleomorphic nuclei and oncocytic cytoplasm. (e) Tumor cells are immunohistochemically positive for mucin protein, MUC1. (f) Mucin protein MUC5AC is positive for tumor cells under immunohistochemical stain.

The immunophenotypes of the patient’s metastatic brain tumor were almost identical to those of the pancreatic tumors, except that they showed strong MUC6 staining. Additionally, both brain and pancreatic tumors showed a G12V (GGT → GTT) mutation in codon 12 of exon 1 of the KRAS gene [NCBI ID:3845] (data not shown). Taken together, these findings suggested a final diagnosis of oncocytic-type intraductal papillary mucinous neoplasm (IPMN)-derived invasive oncocytic carcinoma with brain metastasis [2, 3], staged as T3N0M1.

After the operation, the patient received combined chemotherapy and radiotherapy (CCRT) consisting of irradiation of the whole brain with 3000 cGy, plus a boost of 1500 cGy divided into 5 doses; radiation of the pancreatic tumor bed with 5040 cGy divided into 28 doses, and chemotherapy based on cisplatin and 5-fluorouracil (5-FU).

During follow-up, no recurrence or metastasis was noted in the abdomen or elsewhere, with the exception of residual brain metastases, which presented with stationary status. The performance status of this patient remains good at the time of writing, 20 months after the operation.

Discussion

Oncocytic-type intraductal papillary mucinous neoplasm (IPMN), first identified by Ohhashi et al. [4] in 1992 and first recognized by the World Health Organization (WHO) in 1996, is characterized by the presence of mucin-producing epithelial cells and cystic dilation in the pancreatic ducts. IPMNs represent more than one-third of all cystic neoplasms of the pancreas but less than 1% of all pancreatic tumors [5, 6]. The malignancy potential of IPMNs is low; they are categorized histologically as low-grade, moderate-grade, high-grade, or invasive ductal carcinomas (IPMN-INV) [2, 7]. Although IPMN is believed to progress slowly and to have a better prognosis after resection than pancreatic duct carcinoma (PDAC) [8, 9], resected IPMNs have been found to include PDAC in 40% to 60% of cases [2, 1012]. On the basis of previous reports, the progression time from IPMN to PDAC varies, ranging from 5 to 20 years [10, 13, 14].

IPMN-derived PDACs have been divided into three distinctive subtypes: colloid carcinoma, oncocytic carcinoma, and tubular carcinoma [15]. Some studies have shown that IPMNs associated with invasive carcinomas result in better survival rates than conventional PDAC [16, 17]. However, a recent matched-control study conducted by Yopp et al. showed that while IPMNs with invasive colloid carcinoma had a better prognosis than conventional PDAC [18], IPMNs with invasive tubular carcinoma had a prognosis comparable to that of conventional PDAC. Mino-Kenudson et al. further demonstrated that IPMNs with invasive colloid and oncocytic carcinoma had better survival rates than conventional PDAC, while IPMNs with invasive tubular carcinoma had a survival rate similar to that of conventional PDAC [15].

Here, we report a patient diagnosed with invasive oncocytic carcinoma derived from the oncocytic type of IPMN combined with sole brain metastasis, initially presenting with neurologic symptoms. As shown in a previous study, pancreatic cancer metastasizes predominantly to the liver and peritoneal cavity, as is usually found in locally advanced PDAC [19]. The incidence of brain metastases from pancreatic cancer is very low, with most cases being found post-mortem along with metastasis to places in addition to the brain [20, 21]. Olson et al. reported the first ante-mortem case of PDAC with brain metastasis [22]. Recently, Marco et al. reported a case with PDAC staged as T3N1, in which the patient underwent R0 resection [radical resection ] and subsequent adjuvant chemoradiation. Two years later, brain metastasis occurred and gemcitabine-based chemotherapy was given [23]. To our knowledge, this is the first case of IPMN-derived PDAC with sole brain metastasis. Generally, the treatment for locally advanced PDAC or PDAC with metastasis is palliative, and the median survival time is within 10 months under current standard treatments (mostly gemcitamine-based chemotherapy) [24]. To the contrary, Vazquez et al. recently reported that patients with adrenal metastasis from pancreatic cancer seemed to be benefited by resection of metastatic and origin sites [25]. Patients with pancreatic cancer with one-sided liver metastasis used to undergo the Whipple operation and hepatectomy; however, no obvious improvement in survival has been reported. Some studies have shown that chemoradiotherapy could be more beneficial to patients than radiotherapy alone [26, 27]. Used as a single agent to treat advanced PDAC, 5-FU has been studied extensively since the 1950s, with a range of objective response rates, varying from 0% to 67% [28]: 5-FU has also been combined with other agents, such as doxorubicin, cisplatin, cyclophosphamide, methotrexate, vincristine, and mitomycin, to treat advanced PADC. However, no significant survival benefit has been observed [29].

In the present case, our patient initially presented with neurologic symptoms and so was treated initially on the assumption that he was suffering from a brain abscess. After serial examinations, PDAC with brain metastasis was highly suspected. Although radical therapy for this situation was not feasible, due to the previous subtotal excision of the metastatic brain lesion and the fact that no other metastasis was found after a series of examinations, after discussion with his family, the Whipple operation was conducted and his final local stage was, surprisingly, T3N0. Subsequent radiotherapy and a combination of cisplatin and 5-FU chemotherapy were given and, at present, this patient is still alive with good performance status 2 years after surgery.

Conclusions

On the basis of this case, we suggest that an aggressive therapeutic strategy may benefit some IPMN-derived PDAC patients presenting solely with brain metastasis. IPMN-derived PDAC with sole brain metastasis warrants individual treatment.

Consent

This study has been approved by Chang Gung memorial hospital IRB board. The approved IRB number is 100-2977B. A copy of the approval of IRB is available for review by the Editor-in-Chief of this journal.

Authors’ information

Huang-Yang Chen, Kun-Chun Chiang and Chi-Chang Yu are Co-first authors.

Notes

Abbreviations

CCRT: 

Combined chemotherapy and radiotherapy

CDX2: 

Caudal-related homeobox transcription factor 2

CT: 

Computed tomography

5-FU: 

5-fluorouracil

IPMN: 

Intraductal papillary mucinous neoplasm

MR: 

Magnetic resonance

MRCP: 

Cholangiopancreaticography

PDAC: 

Pancreatic duct carcinoma

TTF1: 

Thyroid transcription factor 1

WHO: 

World Health Organization.

Declarations

Authors’ Affiliations

(1)
General Surgery Department, Chang Gung Memorial Hospital
(2)
Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University
(3)
General Surgery Department, Chang Gung Memorial Hospital
(4)
Department of Pathology, Chang Gung Memorial Hospital
(5)
Department of Radiology, Chang Gung Memorial Hospital
(6)
Department of Radiation Oncology, Chang Gung Memorial Hospital
(7)
Department of Gastroenterolgy, Chang Gung Memorial Hospital
(8)
Department of Neurosurgery, Chang Gung Memorial Hospital
(9)
Department of Hematology and Oncology, Chang Gung Memorial Hospital
(10)
200, Lane 208

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.View ArticlePubMedGoogle Scholar
  2. Hruban RH, Pitman MB, Klimstra DS: Tumors of the Pancreas. Atlas of Tumor Pathology, 4th series, fascicle 6. Washington: Proceedings of the American Registry of Pathology. 2007Google Scholar
  3. Grutzmann R, Niedergethmann M, Pilarsky C, Kloppel G, Saeger HD: Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist. 2010, 15: 1294-1309. 10.1634/theoncologist.2010-0151. 10.1634/theoncologist.2010-0151PubMed CentralView ArticlePubMedGoogle Scholar
  4. Ohhashi K, Murakami Y, Maruyama M, Takekoshi T, Ohta H, Ohhashi I: Four cases of mucous secreting pancreatic cancer. Prog Dig Endosc. 1982, 20: 348-351.Google Scholar
  5. Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw AL: Cystic neoplasms of the pancreas. N Engl J Med. 2004, 351: 1218-1226. 10.1056/NEJMra031623. 10.1056/NEJMra031623 351/12/1218View ArticlePubMedGoogle Scholar
  6. Belyaev O, Seelig MH, Muller CA, Tannapfel A, Schmidt WE, Uhl W: Intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol. 2008, 42: 284-294. 10.1097/MCG.0b013e3180500761PubMedGoogle Scholar
  7. Kloppel GES, Solcia E, Longnecker DS, Capella C, Sobin LH: World Health Organization. Institutional Histological Classification of Tumors. Histological Typing of Tumors of the Exocrine Pancreas. 1996, Berlin: Springer-VerlagView ArticleGoogle Scholar
  8. Obara T, Maguchi H, Saitoh Y, Itoh A, Arisato S, Ashida T, Nishino N, Ura H, Namiki M: Mucin-producing tumor of the pancreas: natural history and serial pancreatogram changes. Am J Gastroenterol. 1993, 88: 564-569.PubMedGoogle Scholar
  9. Levy P, Jouannaud V, O'Toole D, Couvelard A, Vullierme MP, Palazzo L, Aubert A, Ponsot P, Sauvanet A, Maire F, Hentic O, Hammel P, Ruszniewski P: Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol. 2006, 4: 460-468. 10.1016/j.cgh.2006.01.018. 10.1016/j.cgh.2006.01.018]View ArticlePubMedGoogle Scholar
  10. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD: Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004, 239: 788-797. 10.1097/01.sla.0000128306.90650.aa. discussion 797-789PubMed CentralView ArticlePubMedGoogle Scholar
  11. D'Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC: Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg. 2004, 239: 400-408. 10.1097/01.sla.0000114132.47816.dd.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Raut CP, Cleary KR, Staerkel GA, Abbruzzese JL, Wolff RA, Lee JH, Vauthey JN, Lee JE, Pisters PW, Evans DB: Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol. 2006, 13: 582-594. 10.1245/ASO.2006.05.002. 10.1245/ASO.2006.05.002View ArticlePubMedGoogle Scholar
  13. Z'Graggen K, Rivera JA, Compton CC, Pins M, Werner J: Fernandez-del Castillo C, Rattner DW, Lewandrowski KB, Rustgi AK, Warshaw AL: Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg. 1997, 226: 491-498. 10.1097/00000658-199710000-00010. discussion 498–500PubMed CentralView ArticlePubMedGoogle Scholar
  14. Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, Pederzoli P, Warshaw AL: Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004, 239: 678-685. 10.1097/01.sla.0000124386.54496.15. discussion 685-677PubMed CentralView ArticlePubMedGoogle Scholar
  15. Mino-Kenudson M, Fernandez-Del Castillo C, Baba Y, Valsangkar NP, Liss AS, Hsu M, Correa-Gallego C, Ingkakul T, Johnston RP, Turner BG, Androutsopoulos V, Deshpande V, McGrath D, Sahani DV, Brugge WR, Ogino S, Pitman MB, Warshaw AL, Thayer SP: Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011, 60: 1712-1720. 10.1136/gut.2010.232272. 10.1136/gut.2010.232272PubMed CentralView ArticlePubMedGoogle Scholar
  16. Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N: Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Pancreas. 2006, 32: 281-287. 10.1097/01.mpa.0000202955.33483.e2. 10.1097/01.mpa.0000202955.33483View ArticlePubMedGoogle Scholar
  17. Maire F, Hammel P, Terris B, Paye F, Scoazec JY, Cellier C, Barthet M, O'Toole D, Rufat P, Partensky C, Cuillerier E, Levy P, Belghiti J, Ruszniewski P: Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002, 51: 717-722. 10.1136/gut.51.5.717.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Yopp AC, Katabi N, Janakos M, Klimstra DS, D'Angelica MI, DeMatteo RP, Fong Y, Brennan MF, Jarnagin WR, Allen PJ: Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011, 253: 968-974. 10.1097/SLA.0b013e318214bcb4. 10.1097/SLA.0b013e318214bcb4View ArticlePubMedGoogle Scholar
  19. Hidalgo M: Pancreatic cancer. N Engl J Med. 2010, 362: 1605-1617. 10.1056/NEJMra0901557. 10.1056/NEJMra0901557View ArticlePubMedGoogle Scholar
  20. Lee YT, Tatter D: Carcinoma of the pancreas and periampullary structures, Pattern of metastasis at autopsy. Arch Pathol Lab Med. 1984, 108: 584-587.PubMedGoogle Scholar
  21. Shangai VA, Gavrik Iu V: Metastasis of pancreatic cancer to the brain. Vrach Delo. 1984, 11: 77-79.PubMedGoogle Scholar
  22. Olson ME, Chernik NL, Posner JB: Infiltration of the leptomeninges by systemic cancer, A clinical and pathologic study. Arch Neurol. 1974, 30: 122-137. 10.1001/archneur.1974.00490320010002.View ArticlePubMedGoogle Scholar
  23. Caricato M, Borzomati D, Ausania F, Garberini A, Rabitti C, Tonini G, Coppola R: Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology. 2006, 6: 306-308. 10.1159/000092693. 10.1159/000092693View ArticlePubMedGoogle Scholar
  24. Renouf D, Moore M: Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther. 2010, 10: 529-540. 10.1586/era.10.21. 10.1586/era.10.21View ArticlePubMedGoogle Scholar
  25. Vazquez BJ, Richards ML, Lohse CM, Thompson GB, Farley DR, Grant CS, Huebner M, Moreno J: Adrenalectomy improves outcomes of selected patients with metastatic carcinoma. World J Surg. 2012, 36: 1400-1405. 10.1007/s00268-012-1506-3.View ArticlePubMedGoogle Scholar
  26. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007, 25: 326-331. 10.1200/JCO.2006.07.5663. 10.1200/JCO.2006.07.5663View ArticlePubMedGoogle Scholar
  27. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, Ghaneh P: Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007, 96: 1183-1190. 10.1038/sj.bjc.6603719. 10.1038/sj.bjc.6603719PubMed CentralView ArticlePubMedGoogle Scholar
  28. Carter SK, Comis RL: The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev. 1975, 2: 193-214. 10.1016/S0305-7372(75)80003-X.View ArticlePubMedGoogle Scholar
  29. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 1990, 65: 2207-2212. 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y.View ArticlePubMedGoogle Scholar

Copyright

© Chiang et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.